Navigation Links
BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System

BOCA RATON, Fla., Aug. 19 /PRNewswire/ -- The NEWTON™ Intervertebral Body Spacer System is comprised of a complete line of lumbar spinal spacers that allow anterior, posterior or lateral insertion angles to reach the intervertebral disc space.  Each implant is designed with a large central window for optimum graft placement. Initial size offerings range from 7 to 15mm high and 7 to 45mm wide in both parallel and lordotic configurations.  Through the use of a minimal-exposure patent-pending tube system, the NEWTON™ devices are implanted into the intervertebral space to provide stabilization and facilitate fusion.  Lawrence Binder, President of Binder Biomedical, Inc. (BBI) stated, "Given the implant size ranges and instruments offered, the NEWTON™ system gives surgeons the option of a less invasive approach to treat patients, where traditional instrumentation may require a longer, more traumatic surgery."

The NEWTON™ System is manufactured using the PEEK-OPTIMA® polymer from Invibio Biomaterial Solutions.  BBI has entered a supply assurance agreement with Invibio, the leader in orthopedic biomaterials, to provide its proprietary PEEK-OPTIMA® polymer for use in the NEWTON™ devices.  All devices are manufactured in FDA registered facilities located in the USA.

By incorporating a unique approach to rapid product development, BBI combines clinical feedback and industry experience to offer continuous streamlined product improvements to the spine market.  This Alpha launch of the NEWTON™ system will be followed with a full launch expected by the fourth quarter 2010. For more information on Binder Biomedical, Inc. and the NEWTON™ system please contact:

Binder Biomedical, Inc. is a privately held medical device company located in Boca Raton, Florida. Founded on the basis of combining quality engineering with surgeon innovation, the company provides surgeons with the highest quality medical devices for the treatment of complex orthopedic and neurological spinal disorders. Their development efforts are concentrated on products which incorporate advanced minimal exposure techniques, with the goal of providing better overall patient care. For more information about Binder Biomedical, Inc. please visit their website at:

SOURCE Binder Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Competitive Technologies Selects RF
3. Binder as Public Relations Agency of Record
4. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):